The Indian government is closely monitoring the West Asia crisis and may extend relief measures for pharmaceutical exporters beyond June 30, 2026, according to Ravi Teja, deputy director of the Ministry of Commerce and Industry. The government has enacted five measures to mitigate the impact of the crisis, including a full customs duty exemption on critical petrochemical inputs such as ammonia and methanol. This initiative aims to ensure the uninterrupted availability of essential materials and prevent rising production costs. In FY26, India's pharmaceutical exports surpassed $31.1 billion, a slight increase from $30.5 billion in FY25. The government is also promoting trade facilitation through the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and negotiating for broader international acceptance of the Indian Pharmacopoeia. Currently recognized in only 22-23 countries, this effort aims to help Indian companies diversify their markets and reduce reliance on the US, which accounts for about $10.5 billion of India's total pharmaceutical exports. India is the third-largest global producer of pharmaceuticals, supplying 20% of the world's generics demand and exporting to over 200 countries.